Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
2600- Ba,    Baicalein Induces Apoptosis and Autophagy via Endoplasmic Reticulum Stress in Hepatocellular Carcinoma Cells
- in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, Bel-7402
ER Stress↑, Bcl-2↓, Ca+2↑, JNK↑, CHOP/DDIT3↑, Casp9↑, Casp3↑, PARP↑, Apoptosis↑, UPR↑,
2599- Ba,    Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, Apoptosis↑, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IKKα↓, IKKα↑, PI3K↓, MMP↓, TumAuto↑, TumVol↓, TumW↓,
2598- Ba,    Baicalein inhibits melanogenesis through activation of the ERK signaling pathway
- in-vitro, Melanoma, B16-F10
other↓, other?, ERK↑,
2597- Ba,    Baicalein – An Intriguing Therapeutic Phytochemical in Pancreatic Cancer
- Review, PC, NA
chemoP↑, ChemoSen↑, 12LOX?, Bcl-2↓, BAX↑, Mcl-1↓, ERK↓, Prx6↑, Dose↝, BioAv↓, eff↑,
2625- Ba,  LT,    Baicalein and luteolin inhibit ischemia/reperfusion-induced ferroptosis in rat cardiomyocyte
- in-vivo, Stroke, NA
*lipid-P↓, *ACSL4∅, *NRF2∅, *GPx4∅, *Ferroptosis↓, *ROS↓, *MDA↓, *eff↑, *HO-1∅,
2628- Ba,  Cisplatin,    Baicalein alleviates cisplatin-induced acute kidney injury by inhibiting ALOX12-dependent ferroptosis
- in-vitro, Nor, HK-2
*RenoP↑, *12LOX↓, *Ferroptosis↓,
2629- Ba,    Baicalein, a Component of Scutellaria baicalensis, Attenuates Kidney Injury Induced by Myocardial Ischemia and Reperfusion
- in-vivo, Nor, NA
*RenoP↑, *Apoptosis↓, *TNF-α↓, *IL1↓, *Bcl-2↑, *BAX↓, *Akt↑,
2630- Ba,    Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice
- in-vivo, Nor, NA
*RenoP↑, *uricA↓, *ROS↓, EMT↓,
2622- Ba,  Cisplatin,  Rad,    Natural Baicalein-Rich Fraction as Radiosensitizer in Combination with Bismuth Oxide Nanoparticles and Cisplatin for Clinical Radiotherapy
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
RadioS↑,
2627- Ba,  Cisplatin,    Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney Injury by Up-Regulating Antioxidant Defenses and Down-Regulating the MAPKs and NF-κB Pathways
RenoP↑, *iNOS↑, *TNF-α↓, *IL6↓, *NF-kB↓, *MAPK↓, *ERK↓, *JNK↓, *antiOx↑, *NRF2↓, *HO-1↑, *Cyt‑c∅, *Casp3∅, *Casp9∅, *PARP∅,
2620- Ba,    Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review
- Review, GC, NA
Hif1a↓, HK2↓, LDHA↓, PDK1 / PDPK1↓, p‑Akt↓, PTEN↑, GlucoseCon↓, lactateProd↓, Glycolysis↓,
2619- Ba,    Tumor cell membrane-coated continuous electrochemical sensor for GLUT1 inhibitor screening
- in-vitro, HCC, HepG2 - in-vitro, GBM, U87MG - in-vitro, BC, MGC803 - in-vitro, Lung, A549
GLUT1↓, TumCP↓,
2618- Ba,    Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer
- in-vitro, Lung, H1299 - in-vivo, Lung, A549
TumCG↓, TumCP↓, Apoptosis↑, GLUT1↓, GLS↓, mTOR↓, *toxicity∅, cl‑Casp9↓, cl‑Casp3↓, GSH↓, GlutMet↓,
2617- Ba,    Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review
- Review, Var, NA
Ca+2↑, MMP2↓, MMP9↓, Vim↓, Snail↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, i-ROS↑, Bcl-2↓, BAX↑, Cyt‑c↑, Casp3↑, Casp9↑, STAT3↓, IL6↓, MMP2↓, MMP9↓, NOTCH↓, PPARγ↓, p‑NRF2↓, HK2↓, LDHA↓, PDK1 / PDPK1↓, Glycolysis↓, PTEN↑, Akt↓, Hif1a↓, MMP↓, VEGF↓, VEGFR2/KDR/Flk1↓, TOP2↓, uPA↓, TIMP1↓, TIMP2↓, cMyc↓, TrxR↓, ASK1↑, Vim↓, ZO-1↑, E-cadherin↑, SOX2↓, OCT4↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, XIAP↓,
2626- Ba,    Molecular targets and therapeutic potential of baicalein: a review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
AntiCan↓, *neuroP↑, *cardioP↑, *hepatoP↑, *RenoP↑, TumCCA↑, CDK4↓, cycD1/CCND1↓, cycE/CCNE↑, BAX↑, Bcl-2↓, VEGF↓, Hif1a↓, cMyc↓, NF-kB↓, ROS↑, BNIP3↑, *neuroP↑, *cognitive↑, *NO↓, *iNOS↓, *COX2/PTGS2↓, *PGE2↓, *NRF2↑, *p‑AMPK↑, *Ferroptosis↓, *lipid-P↓, *ALAT↓, *AST↓, *Fas↓, *BAX↓, *Apoptosis↓,
2616- Ba,    The Role of HK2 in Tumorigenesis and Development: Potential for Targeted Therapy with Natural Products
- Review, Var, NA
Glycolysis↓, HK2↓, LDHA↓, PDK1 / PDPK1↓, PTEN↑,
2615- Ba,    The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways
- Review, Var, NA
*AntiCan↓, *Inflam↓, TumCP↓, NF-kB↓, PPARγ↑, TumCCA↑, JAK2↓, STAT3↓, TumCMig↓, Glycolysis↓, MMP2↓, MMP9↓, selectivity↑, VEGF↓, Hif1a↓, cMyc↓, ChemoSen↑, ROS↑, p‑mTOR↓, PTEN↑,
2614- Ba,    Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders
- Review, NA, NA
*toxicity↓, *antiOx↑, *Inflam↓, *ROS↓, *NF-kB↓, *MCP1/CCL2↓, *hepatoP↑, *neuroP↑,
2613- Ba,    Hepatoprotective Effect of Baicalein Against Acetaminophen-Induced Acute Liver Injury in Mice
- in-vivo, Nor, NA
*hepatoP↑, *MDA↓, *SOD↑, *Catalase↑, *GSH↑, *MAPK↓, *p‑JAK2↓, *p‑STAT3↓, *ALAT↓, *AST↓, *ROS↓, *antiOx↑,
2612- Ba,  MF,    The effect of a static magnetic field and baicalin or baicalein interactions on amelanotic melanoma cell cultures (C32)
- in-vitro, Melanoma, NA
SOD1↑, SOD2↑, GPx1↑, Dose?, eff↝, SOD1↓, SOD2↓, GPx1↓,
2289- Ba,  Rad,    Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A
- in-vitro, ESCC, KYSE150
TumCP↓, TumCMig↓, Glycolysis↓, cycD1/CCND1↓, CDK4↓, ECAR↓, TumCCA↑, HK1↓, ALDH↓, ALDOA↓, PKM2↓, Hif1a↓,
2292- Ba,  BA,    Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: A comprehensive review with future perspectives
- Review, Var, NA
AntiCan↑, *toxicity↓, BioAv↝, BioAv↓, *ROS↓, *TLR2↓, *NF-kB↓, *NRF2↑, *antiOx↑, *Inflam↓, HDAC1↓, HDAC8↓, Wnt↓, β-catenin/ZEB1↓, PD-L1↓, Sepsis↓, NF-kB↓, LOX1↓, COX2/PTGS2↓, VEGF↑, PI3K↓, Akt↓, mTOR↓, MMP2↓, MMP9↓, SIRT1↑, AMPK↑,
2293- Ba,    Baicalein suppresses inflammation and attenuates acute lung injury by inhibiting glycolysis via HIF‑1α signaling
- in-vitro, Nor, MH-S - in-vivo, NA, NA
*Hif1a↓, *Glycolysis↓, *Inflam↓, *HK2↓, *PFK1↓, *PKM2↓,
2294- Ba,    Baicalein attenuates cardiac hypertrophy in mice via suppressing oxidative stress and activating autophagy in cardiomyocytes
- in-vivo, Nor, NA
*Catalase↑, *ROS↓, *cardioP↑, *FOXO3?,
2295- Ba,  5-FU,    Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway
- in-vitro, GC, AGS
ChemoSen↑, HK2↓, LDHA↓, PDK1 / PDPK1↓, Akt↓, PTEN↑, Hif1a↓, Glycolysis↓, ROS↑, CHOP/DDIT3↑,
2296- Ba,    The most recent progress of baicalein in its anti-neoplastic effects and mechanisms
- Review, Var, NA
CDK1↓, Cyc↓, p27/CDKN1B↑, P21↑, P53↑, TumCCA↑, TumCI↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Vim↓, LC3A↑, p62↓, p‑mTOR↓, PD-L1↓, CAFs/TAFs↓, VEGF↓, ROCK1↓, Bcl-2↓, Bcl-xL↓, BAX↑, ROS↑, cl‑PARP↑, Casp3↑, Casp9↑, PTEN↑, MMP↓, Cyt‑c↑, Ca+2↑, PERK↑, IRE1↑, CHOP/DDIT3↑, Copper↑, Snail↓, Vim↓, Twist↓, GSH↓, NRF2↓, HO-1↓, GPx4↓, XIAP↓, survivin↓, DR5↑,
2297- Ba,    Significance of flavonoids targeting PI3K/Akt/HIF-1α signaling pathway in therapy-resistant cancer cells – A potential contribution to the predictive, preventive, and personalized medicine
- Review, Var, NA
Glycolysis↓, Hif1a↓, PKM2↓, RadioS↑,
2298- Ba,    Flavonoids Targeting HIF-1: Implications on Cancer Metabolism
- Review, Var, NA
TumCG↓, TumCP↓, Hif1a↓, VEGF↓, ChemoSen↑, Glycolysis↓, HK2↓, PDK1 / PDPK1↓, LDHA↓, p‑Akt↓, PTEN↑,
2290- Ba,    Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer
- Review, GI, NA
p‑mTOR↓, p‑Akt↓, p‑IKKα↓, NF-kB↓, PI3K↓, Akt↓, ROCK1↓, GSK‐3β↓, CycB/CCNB1↓, cycD1/CCND1↓, cycA1/CCNA1↑, CDK4↓, P53↑, P21↑, TumCCA↑, MMP2↓, MMP9↓, EMT↓, Hif1a↓, Shh↓, PD-L1↓, STAT3↓, IL1β↓, IL2↓, IL6↓, PKM2↓, HDAC10↓, P-gp/ABCB1↓, Bcl-xL↓, eff↓, BioAv↓, BioAv↑,
2291- Ba,  BA,    Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition
- in-vitro, Melanoma, SK-MEL-28 - in-vitro, Melanoma, A375
LDHA↓, ENO1↓, PKM2↓, GLUT1↓, GLUT3↓, HK2↓, PFK1↓, GPI↓, TPI↓, GlucoseCon↓, TumCG↓, TumCP↓, mTORC1↓, Hif1a↓, Ki-67↓,
2391- Ba,    Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors
- Review, GC, NA
Hif1a↓, PKM2↓, RadioS↑, Glycolysis↓, PAK↓,
2389- BA,    Baicalin alleviates lipid accumulation in adipocytes via inducing metabolic reprogramming and targeting Adenosine A1 receptor
- in-vitro, Obesity, 3T3
*ECAR↑, *OCR↓, *p‑AMPK↑, *p‑ACC↑, *Glycolysis↑, *lipidDe↓, *SREBP1/SREBF1↓, *FAO↑, *HK2↑, *PKM2↑, *LDHA↑, *PDKs↓, *ACC↓,
5554- BBM,  SRF,    Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells
- in-vitro, HCC, NA
ChemoSen↑, STAT3↓,
5536- BBM,    Regulation of Cell-Signaling Pathways by Berbamine in Different Cancers
- Review, Var, NA
JAK↝, STAT3↓, p‑CaMKII ↓, TGF-β↑, Smad1↑, ChemoSen↑, RadioS↑, TumCI↓, TumCMig↓, ROS↑, NRF2↓, SOD2↓, GPx1↓, HO-1↓,
5537- BBM,    CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine
- in-vitro, CLL, NA
CaMKII ↓, NF-kB↓, IKKα↓, p‑STAT3↓,
5538- BBM,    Stabilization of the c-Myc protein by CAMKIIγ promotes T cell lymphoma
- Review, lymphoma, NA
CaMKII ↓, cMyc↝,
5539- BBM,    Berbamine suppresses cell viability and induces apoptosis in colorectal cancer via activating p53-dependent apoptotic signaling pathway
- vitro+vivo, CRC, SW480
tumCV↓, TumCCA↑, MMP↓, P53↑, Casp3↑, Casp9↑, BAX↑, PARP↑, Bcl-2↓, TumVol↑,
5540- BBM,    Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways
- vitro+vivo, NSCLC, NA
TumCMig↓, TumCI↓, PI3K↓, Akt↓, MDM2↓, TumCP↓, TumMeta↓,
5541- BBM,    Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
TumCP↓, TumCCA↑, Apoptosis↑, BRD4↓, selectivity↑, TumCG↓, cMyc↓,
5542- BBM,    Pharmacological profiling of a berbamine derivative for lymphoma treatment
- vitro+vivo, lymphoma, NA
CaMKII ↓, TumCG↓, cMyc↓, ROS↑, UPR↑, ER Stress↑, PERK↑, BioAv↑, toxicity↓,
5543- BBM,    Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo
- in-vivo, Lung, B16-F10 - vitro+vivo, Lung, A549 - in-vitro, BC, MDA-MB-231
BioAv↓, Half-Life↓, eff↑, TumMeta↓, TumCP↓, TumCG↓, Apoptosis↑, TumCCA↑, MMP2↓, MMP9↓, VEGF↓, Bcl-2↓, eff↑, EPR↑,
5544- BBM,    Berbamine promotes macrophage autophagy to clear Mycobacterium tuberculosis by regulating the ROS/Ca2+ axis
- in-vitro, AML, THP1
ROS↑, Ca+2↑,
5546- BBM,    Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca²⁺/calmodulin-dependent protein kinase II
- vitro+vivo, Liver, NA
TumCP↓, CaMKII ↓,
5555- BBM,    Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells
- vitro+vivo, RCC, NA
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, toxicity↓, FTO↑,
5556- BBM,    Berbamine, a novel nuclear factor κB inhibitor, inhibits growth and induces apoptosis in human myeloma cells
- in-vitro, Melanoma, NA
TumCP↓, eff↑, TumCCA↑, IKKα↓, p65↓, Bcl-xL↓, BID↓, survivin↓,
5547- BBM,    Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway
- in-vitro, CRC, HT29
tumCV↓, selectivity↑, Casp3↑, Casp9↑, Bax:Bcl2↑, ATG5↑, Beclin-1/ATG6↑, TumCP↓, MEK↓, ERK↓,
5549- BBM,    Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells
- in-vitro, GBM, NA
eff?, tumCV↓, TumCG↓, ROS↑, P53↑, CSCs↓, CD133↓, ALDH1A1↓, Nanog↓, SOX2↓, OCT4↓, CDK1↓, CaMKII ↓, STAT3↓, Akt↓, ERK↓,
5550- BBM,  docx,  Chit,    Co-Delivery of Docetaxel and Berbamine by Chitosan/Sulfobutylether-β-Cyclodextrin Nanoparticles for Enhancing Bioavailability and Anticancer Activities
- in-vivo, Var, NA
eff↑, BioAv↑, Apoptosis↑, survivin↓,
5551- BBM,    Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis
- vitro+vivo, Bladder, NA
tumCV↓, TumCP↓, TumCCA↑, P21↑, p27/CDKN1B↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, EMT↓, TumMeta↓, p65↓, p‑p65↓, IKKα↓, NF-kB↑, ROS↑, NRF2↓, HO-1↓, SOD2↓, GPx1↓, Bax:Bcl2↑, TumVol↓,
5552- BBM,    Effects of berbamine against myocardial ischemia/reperfusion injury: Activation of the 5' adenosine monophosphate‐activated protein kinase/nuclear factor erythroid 2‐related factor pathway and changes in the mitochondrial state
- in-vivo, Stroke, NA
*eff↑, *ROS↓, *mtDam↓, *AMPK↑, *NRF2↑, *NADPH↑, *HO-1↑, *cardioP↑,

Showing Research Papers: 1201 to 1250 of 8263
Prev Page 25 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8263

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Copper↑, 1,   GPx1↓, 3,   GPx1↑, 1,   GPx4↓, 1,   GSH↓, 2,   HK1↓, 1,   HO-1↓, 3,   NRF2↓, 3,   p‑NRF2↓, 1,   Prx6↑, 1,   ROS↑, 9,   i-ROS↑, 1,   SOD1↓, 1,   SOD1↑, 1,   SOD2↓, 3,   SOD2↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MEK↓, 1,   MMP↓, 4,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX?, 1,   ALDOA↓, 1,   AMPK↑, 1,   cMyc↓, 5,   cMyc↝, 1,   ECAR↓, 1,   ENO1↓, 1,   GLS↓, 1,   GlucoseCon↓, 2,   GlutMet↓, 1,   Glycolysis↓, 9,   GPI↓, 1,   HK2↓, 6,   lactateProd↓, 1,   LDHA↓, 6,   PDK1 / PDPK1↓, 5,   PFK1↓, 1,   PKM2↓, 5,   PPARγ↓, 1,   PPARγ↑, 1,   SIRT1↑, 1,   TPI↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 6,   p‑Akt↓, 5,   Apoptosis↑, 6,   ASK1↑, 1,   BAX↑, 5,   Bax:Bcl2↑, 2,   Bcl-2↓, 7,   Bcl-xL↓, 3,   BID↓, 1,   Casp3↑, 5,   cl‑Casp3↓, 1,   Casp9↑, 5,   cl‑Casp9↓, 1,   Cyt‑c↑, 2,   DR5↑, 1,   JNK↑, 1,   Mcl-1↓, 1,   MDM2↓, 1,   p27/CDKN1B↑, 2,   survivin↓, 3,  

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↓, 5,   p‑CaMKII ↓, 1,   PAK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

BRD4↓, 1,   other?, 1,   other↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 3,   ER Stress↑, 2,   IRE1↑, 1,   PERK↑, 2,   UPR↑, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1/ATG6↑, 1,   BNIP3↑, 1,   LC3A↑, 1,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 4,   PARP↑, 2,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

BRD4↓, 1,   CDK1↓, 2,   CDK2↓, 1,   CDK4↓, 3,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   cycE/CCNE↑, 1,   P21↑, 3,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   ALDH1A1↓, 1,   CD133↓, 1,   CSCs↓, 1,   EMT↓, 3,   ERK↓, 3,   ERK↑, 1,   Gli1↓, 1,   GSK‐3β↓, 1,   HDAC1↓, 1,   HDAC10↓, 1,   HDAC8↓, 1,   mTOR↓, 2,   p‑mTOR↓, 5,   mTORC1↓, 1,   Nanog↓, 1,   NOTCH↓, 1,   OCT4↓, 2,   PI3K↓, 4,   PTEN↑, 7,   Shh↓, 2,   Smo↓, 1,   SOX2↓, 2,   STAT3↓, 6,   p‑STAT3↓, 1,   TOP2↓, 1,   TumCG↓, 8,   Wnt↓, 2,  

Migration(tgid=13) ⓘ

Ca+2↑, 4,   CAFs/TAFs↓, 1,   E-cadherin↑, 3,   FTO↑, 1,   Ki-67↓, 1,   MMP2↓, 7,   MMP9↓, 7,   N-cadherin↓, 2,   ROCK1↓, 2,   Smad1↑, 1,   Snail↓, 2,   TGF-β↑, 1,   TIMP1↓, 1,   TIMP2↓, 1,   TumCI↓, 4,   TumCMig↓, 5,   TumCP↓, 15,   TumMeta↓, 3,   Twist↓, 1,   uPA↓, 1,   Vim↓, 4,   ZO-1↑, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EPR↑, 1,   Hif1a↓, 11,   LOX1↓, 1,   VEGF↓, 6,   VEGF↑, 1,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 3,   GLUT3↓, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IKKα↓, 3,   IKKα↑, 1,   p‑IKKα↓, 2,   IL1β↓, 1,   IL2↓, 1,   IL6↓, 2,   JAK↝, 1,   JAK2↓, 1,   NF-kB↓, 7,   NF-kB↑, 1,   p65↓, 2,   p‑p65↓, 1,   PD-L1↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 3,   BioAv↝, 1,   ChemoSen↑, 6,   Dose?, 1,   Dose↝, 1,   eff?, 1,   eff↓, 1,   eff↑, 5,   eff↝, 1,   Half-Life↓, 1,   RadioS↑, 4,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 2,   Ki-67↓, 1,   PD-L1↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 1,   chemoP↑, 1,   RenoP↑, 1,   toxicity↓, 2,   TumVol↓, 2,   TumVol↑, 1,   TumW↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,  
Total Targets: 194

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 4,   Catalase↑, 2,   Ferroptosis↓, 3,   GPx4∅, 1,   GSH↑, 1,   HO-1↑, 2,   HO-1∅, 1,   lipid-P↓, 2,   lipidDe↓, 1,   MDA↓, 2,   NRF2↓, 1,   NRF2↑, 3,   NRF2∅, 1,   ROS↓, 7,   SOD↑, 1,   uricA↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↓, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   ACC↓, 1,   p‑ACC↑, 1,   ACSL4∅, 1,   ALAT↓, 2,   AMPK↑, 1,   p‑AMPK↑, 2,   ECAR↑, 1,   FAO↑, 1,   Glycolysis↓, 1,   Glycolysis↑, 1,   HK2↓, 1,   HK2↑, 1,   LDHA↑, 1,   NADPH↑, 1,   PDKs↓, 1,   PFK1↓, 1,   PKM2↓, 1,   PKM2↑, 1,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   Apoptosis↓, 2,   BAX↓, 2,   Bcl-2↑, 1,   Casp3∅, 1,   Casp9∅, 1,   Cyt‑c∅, 1,   Fas↓, 1,   Ferroptosis↓, 3,   iNOS↓, 1,   iNOS↑, 1,   JNK↓, 1,   MAPK↓, 2,  

DNA Damage & Repair(tgid=10) ⓘ

PARP∅, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   FOXO3?, 1,   p‑STAT3↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,   NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL1↓, 1,   IL6↓, 1,   Inflam↓, 4,   p‑JAK2↓, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 3,   PGE2↓, 1,   TLR2↓, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 2,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   cardioP↑, 3,   cognitive↑, 1,   hepatoP↑, 3,   neuroP↑, 3,   RenoP↑, 4,   toxicity↓, 2,   toxicity∅, 1,  
Total Targets: 79

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page